Reuters logo
10 个月前
BRIEF-Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus infection
2016年10月19日 / 中午12点23分 / 10 个月前

BRIEF-Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus infection

Oct 19 (Reuters) - Eiger BioPharmaceuticals Inc :

* Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus (HDV) infection

* Eiger BioPharmaceuticals - LIMT HDV is currently enrolling at University of Auckland in New Zealand with additional sites planned in Israel , Pakistan Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below